Status:
COMPLETED
Study of Temsirolimus, Topotecan, and Bortezomib
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Advanced Cancer
Eligibility:
All Genders
Phase:
PHASE1
Brief Summary
The goal of this clinical research study is to find the highest tolerable dose of Torisel (temsirolimus), Hycamtin (topotecan hydrochloride), and Velcade (bortezomib) that can be given, in combination...
Detailed Description
The Study Drugs: Temsirolimus is designed to block pathways that control important events such as the growth of blood vessels that are vital for the growth of cancer. This may cause cancer cells to d...
Eligibility Criteria
Inclusion
- Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or have no standard therapy that improves survival by at least three months
- Patients should be at least four weeks or 5 half lives from the last day of chemotherapy, and antibody or other biological therapy, whichever is shorter.
- Patients should be at least four weeks from the last day of therapeutic radiation.
- The Eastern Cooperative Oncology Group (ECOG) performance status \</= 2 or Karnofsky \>/= 60%.
- Patients must have allowable organ and marrow function defined as: Absolute neutrophil count \>/= 1,000/mL, Platelets \>/=75,000/mL, Serum creatinine \</= 2 \* Upper Limit of Normal (ULN), Total bilirubin \</= 2 \* ULN, aminotransferase (ALT or SGPT) \</= 3 \* ULN, Fasting total cholesterol \<= 350 mg/dL and triglyceride level \<= 400 mg/dL.
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and will be advised to avoid pregnancy for 3 months after completion of therapy.
- Ability to understand and the willingness to sign a written informed consent document.
- Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies except for continuing on hormonal therapy in cases of prostate cancer.
- Treatment on this study may begin within 24 hours after Phase 0 dose of temsirolimus.
Exclusion
- Patients with hemoptysis within 28 days prior to entering the study.
- Patients with clinically significant unexplained bleeding within 28 days prior to entering the study.
- Patients with clinically significant cardiovascular disease: • History of CVA within 6 months • Myocardial infarction or unstable angina within 6 months • Unstable angina pectoris
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics on Day 1.
- Pregnant or lactating women.
- History of hypersensitivity to bortezomib or any component of the bortezomib formulation.
- History of hypersensitivity to topotecan or any component of the topotecan formulation.
- History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00770731
Start Date
September 1 2008
End Date
November 1 2012
Last Update
February 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030